Peroxisome Proliferator-Activated Receptor δ: A Target with  a Broad Therapeutic Potential for Drug Discovery by Gregoire, Francine M.
Hindawi Publishing Corporation
PPAR Research
Volume 2008, Article ID 736362, 2 pages
doi:10.1155/2008/736362
Editorial
Peroxisome Proliferator-Activated Receptor δ: A Target with
a Broad Therapeutic Potential for Drug Discovery
Francine M. Gregoire
Department of Biology, Metabolex Inc., Hayward, CA 94545, USA
Correspondence should be addressed to Francine M. Gregoire, fmgregoire@metabolex.com
Received 30 December 2008; Accepted 30 December 2008
Copyright © 2008 Francine M. Gregoire. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
The biology of Peroxisome proliferator-activated receptor
(PPAR) alpha (α) and gamma (γ) has been intensely
scrutinized for the last 20 years and the clinical use of both
PPAR-α (ﬁbrates) and PPAR-γ (thiazolididiones) agonists
hasledtotheunderstandingoftheirkeyroleinthetreatment
ofhypertriglyceridemiaandtype2diabetesmellitus[1,2].In
contrast, the understanding of PPAR delta (δ) biology still
lags behind. The identiﬁcation of small molecule agonists
for PPAR-δ has shed some light on the function of this
ubiquitously expressed receptor in preclinical models and
early clinical studies [3]. They have revealed the multiple
beneﬁts of PPAR-δ activation on lipid disorders, diabetes,
and inﬂammation [3, 4]. However, synthetic PPAR-δ ago-
nists have yet to be marketed for clinical use in humans,
partly due to the burden associated with their clinical
development [3].
InthisspecialissueofPPARResearch,thebroadpotential
of PPAR-δ agonists for the treatment of metabolic disease
is highlighted by 3 key articles. They include a review from
de Lange et al. on the regulation of the oxidative capacity
of muscle by PPAR-δ, an article by Perreault et al. which
tackles opportunities and issues with the development of
PPAR-δ agonist for the treatment of obesity, and ﬁnally
a review from Wang that addresses the eﬀect of PPAR-δ
activation on vascular pathophysiological processes. A key
question regarding the result of PPAR-δ activation, either
via natural or via synthetic ligands, is its eﬀect on cell
proliferation and the risk of inducing cancer. This has been
an area of intense debate as both pro- and antitumorigenic
eﬀects have been reported. This topic is concisely reviewed
in this issue by Muller et al. Last but not least, two interesting
and not well-characterized portions of PPAR-δ biology are
presented. First, as PPAR-δ is expressed at high level in the
brain, Hall et al. investigate the potential neuroprotective
role of PPAR-δ activation in this organ. Second, although
the role of PPAR-δ in embryo implantation was recognized
early on with studies in knockout mice [5], the reproductive
functions of PPAR-δ are still unclear. This topic and the
projectedpotentialapplicationsofPPAR-δ ligandsinassisted
reproductive technology are addressed in Huang’s review.
Taken together, it is obvious that there is an urgent need
for additional basic research to better characterize PPAR-
δ function. The current availability of synthetic ligands
should help to further dissect PPAR-δ-mediated responses
in the brain as well as in other functions not addressed
in this issue, including gut and skin homesotasis. Although
challenges for the development of PPAR-δ agonists remains,
they clearly hold great therapeutic promise, as highlighted by
recent clinical ﬁndings indicating that MBX-8025, one of the
most advanced PPAR-δ agonists currently in phase II clinical
trial for dyslipidemia, displays hypolipidemic features not
observed with the currently available dyslipidemia therapies
[6, 7].
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